Stewart Campbell: Positive data from NP-G2-044 trial in patients with advanced and metastatic solid tumors
Stewart Campbell, Chief Executive Officer at Novita Pharmaceuticals, shared a post on LinkedIn:
“Exciting News from Novita Pharmaceuticals!
I’m thrilled to share that Novita Pharmaceuticals has presented additional positive data from our Phase 2 trial of NP-G2-044 in patients with advanced and metastatic solid tumors at the AACR IO Annual Meeting. The durable efficacy we have observed with our first-in-class fascin inhibitor further support the simultaneous inhibition of metastasis and enhancement of cancer immunotherapy as a promising and innovative approach in cancer treatment with broad applications for many solid tumors that can truly make a difference for patients.
The latest data continue to reinforce the potential of NP-G2-044 in targeting aggressive cancers, and we’re grateful for the opportunity to showcase our findings at this important congress. A huge thank you to our research team, clinical investigators, and patients who make this progress possible!
Check out the full abstract publication
Looking forward to continued advancements as we push forward in the fight against cancer!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023